Overview | Day 1 | Day 2 | Download Brochure
Promising Drug Targets for Diabetes
Novel Approaches for New Therapies
A Closer Look at Incretins
Topic: The Future of Incretins as a Target for Diabetes
Richard E. Pratley, M.D., Professor of Medicine and Director, Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine
Rachele Berria, M.D., M.S.C.I., U.S. Medical Director, Diabetes Franchise, Roche Laboratories
Michael R. Hanley, Ph.D.,Chief Scientific Officer, Amylin Pharmaceuticals, Inc.
Rachele Berria, M.D., Roche Laboratories
Elaine Chiquette, Amylin Pharmaceuticals Inc.
Max Dang, Ph.D., Metabasis Therapeutics, Inc.
Joseph Grimsby, Ph.D., F. Hoffmann-La Roche Inc.
Jesper Gromada, Ph.D., Novartis Institutes for BioMedical Research, Inc.
Michael R. Hanley, Ph.D., Amylin Pharmaceuticals, Inc.
Richard Ho, M.D., Ph.D., Rosa & Co. LLC.
Reid Huber, Ph.D., Metabolic Endocrine Drug Development, Incyte Corporation
Rob Jones, Ph.D., Arena Pharmaceuticals
Julia Lamenzo Ph.D., Harvard University
Daniel Lin, Ph.D., Amgen Inc.
Peter J. Oates, Ph.D., Pfi zer Global Research and Development
Norbert Perrimon, Ph.D., Harvard Medical School
Richard E. Pratley, M.D., University of Vermont College of Medicine
Jean Whaley, Ph.D., Bristol-Myers Squibb